Showing 5301-5310 of 6036 results for "".
- Kubota Vision Introduces Electronic Eyeglasses to Stop Myopia in Childrenhttps://modernod.com/news/kubota-vision-introduces-electronic-eyeglasses-to-stop-myopia-in-children/2477794/Kubota Vision announced positive clinical results from myopia control tests in humans. Utilizing electronic tabletop optical projection devices that embody Kubota Glasses technology, myopically-defocused images were projected on the peripheral retina of subjects to study if progression of myopia
- Avellino Announces A.C.T.S. Program to Help Eye Care and Other Surgical Practices Protect Patients and Staff From COVID-19https://modernod.com/news/avellino-announces-a-c-t-s-program-to-help-eye-care-and-other-surgical-practices-protect-patients-and-staff-from-covid-19/2477792/Avellino announced the rollout of the new A.C.T.S. Program (Active Coronavirus Testing & Safety) designed to help ophthalmology and other elective surgery and procedure-oriented practices safely reopen and resume care while protecting patients and staff from COVID-19 virus transmission. <
- Early Data Show Moderna’s COVID-19 Vaccine Generates Immune Responseshttps://modernod.com/news/first-covid-19-vaccine-tested-in-the-us-shows-promise-in-data-from-eight-people/2477791/Moderna reported positive interim data from a phase 1 study of its vaccine candidate against SARS-CoV-2, with results showing that mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants in the low- and mid-dose cohorts, reaching or exceeding levels generally seen
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not
- Samsung Bioepis Announces 24-Week Interim Results From a Phase 3 Trial of Ranibizumab Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-24-week-interim-results-from-a-phase-3-trial-of-ranibizumab-biosimilar/2477785/Samsung Bioepis announced that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar candidate, to reference ranibizumab in patients with wet age-related macular degeneration (AMD).</
- Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-reports-topline-data-from-phase-2-trial-with-ocs-01-for-treating-inflammation-and-pain-following-cataract-surgery/2477782/Oculis SA reported positive results from its phase 2 SKYGGN study of OCS-01, a novel, high concentration, preservative free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%) for the treatment of inflammation and pain following cataract surgery. OCS-01 has been develope
- AMA Issues Guidance to Physicians on Using COVID-19 Antibody Testshttps://modernod.com/news/ama-issues-guidance-to-physicians-on-using-covid-19-antibody-tests/2477783/As new serology tests for COVID-19 rapidly come to the market, the American Medical Association (AMA) is cautioning physicians about using these tests to make healthcare decisions for individual patients, according to a FierceHealthcare
- MPR and MacuLogix Received A’Design Awardhttps://modernod.com/news/mpr-and-maculogix-received-adesign-award/2477781/MPR and MacuLogix were recognized with the A’Design Platinum Award, the world’s largest design competition, for its work on the AdaptDx Pro, a medical headset by MacuLogix. Launched earlier this year, the device build
- Prevent Blindness Unveils New Brand Identity, Logo and Websitehttps://modernod.com/news/prevent-blindness-unveils-new-brand-identity-logo-and-website/2477772/Prevent Blindness announced the launch of its new brand identity, logo, and website. The launch coincides with the organization’s new “Be a Visionary” campaign: a call to action to join in the sight-saving efforts of Prevent Blindness. The new identity is designed to refl
- Johnson & Johnson Vision Announces Global Initiatives to Support Eye Care Professionals and Patients During COVID-19 and Beyondhttps://modernod.com/news/johnson-johnson-vision-announces-global-initiatives-to-support-eye-care-professionals-and-patients-during-covid-19-and-beyond/2477770/Johnson & Johnson Vision is deploying solutions around the world to help address the challenges facing eye care professionals (ECPs) and their patients amid the COVID-19 pandemic. These support the broader efforts that Johnson & Johnson is taking to curb the crisis, including development